Saquinavir Inhibits the malaria parasite's chloroquine resistance transporter

Rowena E. Martin*, Alice S. Butterworth, Donald L. Gardiner, Kiaran Kirk, James S. McCarthy, Tina S. Skinner-Adams

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    24 Citations (Scopus)

    Abstract

    The antiretroviral protease inhibitors (APIs) ritonavir, saquinavir, and lopinavir, used to treat HIV infection, inhibit the growth of Plasmodium falciparum at clinically relevant concentrations. Moreover, it has been reported that these APIs potentiate the activity of chloroquine (CQ) against this parasite in vitro. The mechanism underlying this effect is not understood, but the degree of chemosensitization varies between the different APIs and, with the exception of ritonavir, appears to be dependent on the parasite exhibiting a CQ-resistant phenotype. Here we report a study of the role of the P. falciparum chloroquine resistance transporter (PfCRT) in the interaction between CQ and APIs, using transgenic parasites expressing different PfCRT alleles and using the Xenopus laevis oocyte system for the heterologous expression of PfCRT. Our data demonstrate that saquinavir behaves as a CQ resistance reverser and that this explains, at least in part, its ability to enhance the effects of CQ in CQ-resistant P. falciparum parasites.

    Original languageEnglish
    Pages (from-to)2283-2289
    Number of pages7
    JournalAntimicrobial Agents and Chemotherapy
    Volume56
    Issue number5
    DOIs
    Publication statusPublished - May 2012

    Fingerprint

    Dive into the research topics of 'Saquinavir Inhibits the malaria parasite's chloroquine resistance transporter'. Together they form a unique fingerprint.

    Cite this